Akari Therapeutics PLC (AKTX) SEC Filings — 2024
23 SEC filings for Akari Therapeutics PLC (AKTX) in 2024.
Filings
- Akari Therapeutics Board Changes Announced — 8-K · Dec 18, 2024
- Akari Therapeutics Appoints New CMO, Adds Director — 8-K · Dec 16, 2024
- Akari Therapeutics Announces Board and Executive Changes — 8-K · Dec 12, 2024
- Patel Amends Akari Therapeutics Stake Filing — SC 13D/A · Dec 6, 2024
- Akari Therapeutics Plc Files Q3 2024 10-Q — 10-Q · Nov 19, 2024
- Akari Therapeutics Plc Files 8-K with Multiple Material Events — 8-K · Nov 14, 2024
- Akari Therapeutics Files 8-K on Shareholder Votes and Filings — 8-K · Nov 8, 2024
- Akari Therapeutics Faces Nasdaq Delisting Warning — 8-K · Oct 4, 2024
- Akari Therapeutics Appoints New CMO, Elects Director — 8-K · Sep 18, 2024
- Akari Therapeutics Files 8-K on Financing and Warrants — 8-K · Sep 6, 2024
- Akari Therapeutics Plc Files 8-K/A for Director and Officer Changes — 8-K/A · Aug 23, 2024
- Akari Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 19, 2024
- Akari Therapeutics Plc Files 8-K on Shareholder Vote — 8-K · Jul 1, 2024
- RPC Pharma Ltd Amends Akari Therapeutics Stake — SC 13D/A · Jun 20, 2024
- Theofilos Charles Steve reports 1.9% stake in Akari Therapeutics — SC 13D · Jun 18, 2024
- Patel Discloses 1.9% Stake in Akari Therapeutics — SC 13D · Jun 7, 2024
- Akari Therapeutics Files 8-K on Officer/Director Changes — 8-K · Jun 5, 2024
- Akari Therapeutics Enters Definitive Agreement, Discloses Equity Sales — 8-K · Jun 4, 2024
- Akari Therapeutics Plc Files Definitive Proxy Statement — DEF 14A · Jun 3, 2024
- Akari Therapeutics Files 8-K on Financials — 8-K · May 16, 2024
- Akari Therapeutics Plc Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 15, 2024
- Akari Therapeutics Announces CMO Departure, Appoints Interim — 8-K · May 7, 2024
- Akari Therapeutics Director Departs, Files 8-K — 8-K · May 1, 2024